LENSAR Management

Management Kriterienprüfungen 3/4

LENSAR's CEO ist Nick Curtis , ernannt in Feb 2012, hat eine Amtszeit von 12.33 Jahren. Die jährliche Gesamtvergütung beträgt $1.17M , bestehend aus 46.4% Gehalt und 53.6% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 6.68% der Aktien des Unternehmens, im Wert von $3.51M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.6 Jahre bzw. 6.3 Jahre.

Wichtige Informationen

Nick Curtis

Geschäftsführender

US$1.2m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	46.4%
Amtszeit als Geschäftsführer	12.3yrs
Eigentum des Geschäftsführers	6.7%
Durchschnittliche Amtszeit des Managements	6.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.3yrs

Jüngste Management Updates

Here's Why Shareholders May Want To Be Cautious With Increasing LENSAR, Inc.'s (NASDAQ:LNSR) CEO Pay Packet

May 01

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing LENSAR, Inc.'s (NASDAQ:LNSR) CEO Pay Packet

May 01

LENSAR, Inc.'s (NASDAQ:LNSR) Shares Leap 33% Yet They're Still Not Telling The Full Story

Feb 22

Here's Why We're Not Too Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Situation

Nov 01

LENSAR GAAP EPS of -$0.67, revenue of $8M

Aug 08

LENSAR (NASDAQ:LNSR) Is In A Good Position To Deliver On Growth Plans

Mar 23

We Think LENSAR (NASDAQ:LNSR) Can Afford To Drive Business Growth

Jul 28

LENSAR EPS misses by $0.23, beats on revenue

May 05

What You Need To Know About LENSAR, Inc.'s (NASDAQ:LNSR) Investor Composition

Feb 25

We're Keeping An Eye On LENSAR's (NASDAQ:LNSR) Cash Burn Rate

Jan 03

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Nick Curtis im Vergleich zu den Einnahmen von LENSAR verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$12m
Dec 31 2023	US$1m	US$541k	-US$14m
Sep 30 2023	n/a	n/a	-US$13m
Jun 30 2023	n/a	n/a	-US$18m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$1m	US$518k	-US$20m
Sep 30 2022	n/a	n/a	-US$21m
Jun 30 2022	n/a	n/a	-US$23m
Mar 31 2022	n/a	n/a	-US$21m
Dec 31 2021	US$1m	US$491k	-US$20m
Sep 30 2021	n/a	n/a	-US$23m
Jun 30 2021	n/a	n/a	-US$21m
Mar 31 2021	n/a	n/a	-US$21m
Dec 31 2020	US$8m	US$448k	-US$20m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$16m
Mar 31 2020	n/a	n/a	-US$15m
Dec 31 2019	US$1m	US$340k	-US$15m

Vergütung im Vergleich zum Markt: NickDie Gesamtvergütung ($USD1.17M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD678.50K).

Entschädigung vs. Einkommen: NickDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Nick Curtis (67 yo)

12.3yrs

Amtszeit

US$1,166,811

Vergütung

Mr. Nicholas T. Curtis serves as the Chief Executive Officer and Director of LensAR Inc since February 2012. Mr. Curtis served as the Chief Commercial Officer of LensAR Inc. from August 2010 until February...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Nicholas Curtis	President	12.3yrs	US$1.17m	6.68% $ 3.4m
Thomas Staab	CFO & Secretary	4.1yrs	US$670.30k	1.12% $ 563.3k
Alan Connaughton	Chief Operating Officer	9.2yrs	US$785.38k	2.28% $ 1.2m
Kendra Wong	Principal Accounting Officer	2.4yrs	keine Daten	0.14% $ 70.6k

6.6yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrenes Management: LNSRDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (6.6 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Nicholas Curtis	President	12.3yrs	US$1.17m	6.68% $ 3.4m
William Link	Independent Chairman	6.6yrs	US$191.91k	4.49% $ 2.3m
Richard Lindstrom	Independent Director	6.3yrs	US$171.91k	1.82% $ 918.2k
Elizabeth O'Farrell	Independent Director	3.3yrs	US$164.91k	0.099% $ 49.9k
Gary Winer	Independent Director	6.2yrs	US$171.41k	0.39% $ 194.7k
William Trattler	Member of Medical Advisory Board	no data	keine Daten	keine Daten
Mark Packer	Member of Medical Advisory Board	no data	keine Daten	keine Daten
Gregory Parkhurst	Member of Medical Advisory Board	no data	keine Daten	keine Daten
Robert Weinstock	Member of Medical Advisory Board	no data	keine Daten	keine Daten
Carlos Buznego	Member of Medical Advisory Board	no data	keine Daten	keine Daten
Mitchell Jackson	Member of Medical Advisory Board	no data	keine Daten	keine Daten
Denise Visco	Member of Medical Advisory Board	no data	keine Daten	keine Daten

6.3yrs

Durchschnittliche Betriebszugehörigkeit

67yo

Durchschnittliches Alter

Erfahrener Vorstand: LNSRDie Vorstandsmitglieder gelten als erfahren (6.3 Jahre durchschnittliche Amtszeit).

LENSAR Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Here's Why Shareholders May Want To Be Cautious With Increasing LENSAR, Inc.'s (NASDAQ:LNSR) CEO Pay Packet

LENSAR, Inc., Annual General Meeting, May 07, 2024

Insufficient new directors

LENSAR, Inc. Announces Retirement of John P. McLaughlin from the Board, Effective October 31, 2023

LENSAR, Inc., Annual General Meeting, Aug 01, 2023

Insider recently bought US$85k worth of stock

Recent updates

First quarter 2024 earnings: EPS exceeds analyst expectations

LENSAR, Inc. to Report Q1, 2024 Results on May 09, 2024

Here's Why Shareholders May Want To Be Cautious With Increasing LENSAR, Inc.'s (NASDAQ:LNSR) CEO Pay Packet

LENSAR, Inc., Annual General Meeting, May 07, 2024

Consensus EPS estimates fall by 42%

Full year 2023 earnings: EPS exceeds analyst expectations

Insufficient new directors

LENSAR, Inc. to Report Q4, 2023 Results on Mar 04, 2024

LENSAR, Inc.'s (NASDAQ:LNSR) Shares Leap 33% Yet They're Still Not Telling The Full Story

Here's Why We're Watching LENSAR's (NASDAQ:LNSR) Cash Burn Situation

Not Many Are Piling Into LENSAR, Inc. (NASDAQ:LNSR) Just Yet

Consensus EPS estimates upgraded to US$1.62 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

LENSAR, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Here's Why We're A Bit Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Situation

New minor risk - Share price stability

LENSAR, Inc. Announces Retirement of John P. McLaughlin from the Board, Effective October 31, 2023

Investors Continue Waiting On Sidelines For LENSAR, Inc. (NASDAQ:LNSR)

Consensus EPS estimates fall by 35%, revenue upgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Shareholder dilution

LENSAR, Inc. to Report Q2, 2023 Results on Aug 09, 2023

LENSAR, Inc., Annual General Meeting, Aug 01, 2023

Insider recently bought US$85k worth of stock

LENSAR, Inc. announced that it has received $20 million in funding from NR-GRI Partners, LP

First quarter 2023 earnings released: US$0.40 loss per share (vs US$0.67 loss in 1Q 2022)

LENSAR, Inc. to Report Q1, 2023 Results on May 15, 2023

This Broker Just Slashed Their LENSAR, Inc. (NASDAQ:LNSR) Earnings Forecasts

Will LENSAR (NASDAQ:LNSR) Spend Its Cash Wisely?

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased by 20% to US$12.00

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

LENSAR, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Here's Why We're Not Too Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Situation

LENSAR, Inc. Announces First Patients Treated with LENSAR's(R) ALLY(TM) Adaptive Cataract Treatment System

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

LENSAR GAAP EPS of -$0.67, revenue of $8M

LENSAR, Inc. to Report Q2, 2022 Results on Aug 08, 2022

LENSAR, Inc.(NasdaqCM:LNSR) dropped from Russell Microcap Value Index

LENSAR, Inc. Receives U.S. FDA Clearance of Ally(Tm) Adaptive Cataract Treatment System

Consensus EPS estimates fall by 31%

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

LENSAR, Inc. to Report Q1, 2022 Results on May 09, 2022

Price target decreased to US$13.50

Consensus forecasts updated

LENSAR, Inc., Annual General Meeting, May 25, 2022

LENSAR (NASDAQ:LNSR) Is In A Good Position To Deliver On Growth Plans

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

LENSAR, Inc. Announces U.S. Food and Drug Administration Acceptance of 510(k) Submission for ALLY

LENSAR, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Third quarter 2021 earnings released: US$0.65 loss per share (vs US$0.64 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.47 loss per share (vs US$4.20 loss in 2Q 2020)

We Think LENSAR (NASDAQ:LNSR) Can Afford To Drive Business Growth

LENSAR, Inc.(NasdaqCM:LNSR) dropped from Russell 2000 Defensive Index

First quarter 2021 earnings released: US$0.56 loss per share (vs US$3.82 loss in 1Q 2020)

LENSAR EPS misses by $0.23, beats on revenue

Full year 2020 earnings released: US$4.28 loss per share (vs US$1.52 loss in FY 2019)

Revenue beats expectations, earnings disappoint

LENSAR, Inc. to Report Q4, 2020 Results on Mar 10, 2021

What You Need To Know About LENSAR, Inc.'s (NASDAQ:LNSR) Investor Composition

LENSAR, Inc Announces Board Appointment

New 90-day low: US$6.64

We're Keeping An Eye On LENSAR's (NASDAQ:LNSR) Cash Burn Rate

LENSAR, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Analyse der Geschäftsführervergütung

Geschäftsführer